Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Brings Full Value Of Cialis In-House With Purchase Of Partner ICOS

Executive Summary

Lilly will acquire its joint venture partner ICOS for approximately $2.1 bil. to gain the full rights to the erectile dysfunction drug Cialis (tadalafil), which the two companies have partnered on since 1998

You may also be interested in...



The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals

Roche and Bristol-Myers Squibb have everyone wondering who will be the next company to buy out its biotech partner

The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals

Roche and Bristol-Myers Squibb have everyone wondering who will be the next company to buy out its biotech partner

Erectile Dysfunction Class Labeling Excludes Causal Link To Vision Loss

FDA's class labeling for oral erectile dysfunction disorder drugs on the incidence of non-arteritic anterior ischemic optic neuropathy notes that it is unknown whether the drugs are connected to the adverse events

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel